Cellectis (NASDAQ:CLLS) Receives News Sentiment Rating of 0.62
Media coverage about Cellectis (NASDAQ:CLLS) has been trending very positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectis earned a daily sentiment score of 0.62 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Trading Lines in Review for Cellectis SA Ads (CLLS) – Wall Street Review (thewallstreetreview.com)
- Cellectis SA (CLLS) Price Above The Cloud: Shows Positive Momentum – Evergreen Caller (evergreencaller.com)
- Cellectis S.A. (CLLS) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Cellectis SA (CLLS) Holds Steady Above Rising Trendline – FLBC … – FLBC News (flbcnews.com)
- Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million – Markets Insider (markets.businessinsider.com)
Several analysts recently commented on the company. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Cellectis in a report on Saturday, June 3rd. Zacks Investment Research cut Cellectis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 4th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $47.00 target price on shares of Cellectis in a report on Wednesday, April 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $39.60.
Shares of Cellectis (CLLS) opened at 28.01 on Monday. The company’s market capitalization is $989.73 million. Cellectis has a one year low of $16.09 and a one year high of $28.77. The company has a 50-day moving average price of $24.00 and a 200 day moving average price of $21.89.
COPYRIGHT VIOLATION NOTICE: “Cellectis (NASDAQ:CLLS) Receives News Sentiment Rating of 0.62” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/07/17/cellectis-nasdaqclls-receives-news-sentiment-rating-of-0-62.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.